Clene announces $7.3M registered direct offering and concurrent private placements

Clene Inc.

Gross proceeds ~$7.3M; shares/pre-funded warrants at $4.713 combined with warrants ($4.82 strike, 5-year term).
Warrants exercisable immediately; lock-up until later of 45 days or FDA meeting outcome announcement.
Directors/officers bought 122,819 shares at $4.875/warrant package; existing investors also participated.
Proceeds to fund clinical development of lead candidate CNM-Au8 (ALS/MS) and general corporate purposes.
Canaccord Genuity acted as sole placement agent; closing expected on or about October 1, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.